Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
Clinical trial NCT06601127 · RECRUITING
Trial details
- NCT number
- NCT06601127
- Sponsor
- Tianjin Institute of Pharmaceutical Research Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-21
- Primary completion
- 2026-04-01
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.